Study Rationale: Differences in the leucine-rich repeat kinase 2 (LRRK2) gene can increase the risk of developing Parkinson’s disease (PD), and there is an abundance of the LRRK2 protein in blood immune cells that regulate inflammation. This project will determine…
Though associated with only a small percentage of total Parkinson’s cases, mutations of the LRRK2 gene are the greatest known genetic contributor to Parkinson’s disease (PD). Researchers are striving to understand the mechanisms of disease related to this mutation because…
Denali Therapeutics — a San Francisco biotech that launched last year focused on neurodegenerative diseases including Parkinson’s — recently announced it has licensed LRRK2 inhibitor compounds from Genentech. These drug candidates may address the dysfunction seen with LRRK2 mutations, the greatest…
Shake It Up Australia Foundation is delighted to announce new funding for world’s best research being conducted at Neuroscience Research Australia (NeuRA). The twelve month research grant funded in partnership with The Michael J. Fox Foundation for Parkinson’s Research will…
The protein leucine-rich repeat kinase 2, or LRRK2, is fast becoming a target of major interest for researchers looking to develop Parkinson’s disease (PD) drugs, for a couple of reasons: For one, mutations in the gene associated with LRRK2 are…
